Role of BATAN in Preparing Radioisotopes and Radiopharmaceuticals for Cancer Diagnosis and Treatment in Indonesia

Abdul Mutalib

Center for Radioisotopes and Radiopharmaceuticals

National Atomic Energy Agency (BATAN)

BATAN and PT Batantek

BATAN A Government R&D Institution

PT Batantek A Government owned Company

BATAN has the following functions :

• To assess and prepare the national policy in the field of research,

development, and the beneficial uses of nuclear energy.

• To develop and utilize production technology of radioisotopes and radiopharmaceuticals for healthcare.

Cyclotron CS30

Nuclear Reactor

Radioisotopes/Radionuclides

Sealed Sources)

Unsealed-Sources)

• Brachytherapy 125I, 103Pd, 192Ir, 198Au

• Radiotherapy 137Cs, 60Co

• Radiopharmaceuticals

• Radionuclide Generators

• Radioassay Kits

• Molecular Radiotracers

Technology of radioisotope production

Brachytherapy Sources developed by BATAN

125I-seed brachytherapy

125I-thermosensitive polymer

198Au-Nanodevice brachytherapy

192Ir HDR/LDR brachytherapy

Physical Characteristics of Brachytherapy Sources

Radionuclide Half-life E (KeV)Physical

Configuration Remarks

Gold-198

Iodine-125

Palladium-103

Iridium-192

2.7 d 412

60 d 35 Seeds Small size; less exposure to personnel

nanodevice Small size; higher dose rate

17 d 23 Seeds Small size; higher dose rate; less exposure to

personnelWire, seeds, cathethers

(afterloading)

74 d 136 – 1060 Wide variety of source strengths and sizes; usually afterloaded

The BATAN’s Facility for Producing Radionuclide of 125I

BATAN’s Laser Welder for preparing 125I and 103Pd seed and 192Ir

needle sealed-sources

125I seed sealed-sources

Brachytherapy of Prostate

Cancer using 125I seeds

Metalic

Radionuclide

Bifunctional

Chelating

Agent

Linker

(Pharmacokinetic Modifier)

Development of Target-Specific Radiopharmaceuticals

(Molecular Targeting Agents)

Non-Metalic

Radionuclide

Targeting Molecule

18F, 123I, 124I,11C, 131I, 211At

67Cu, 90Y, 99mTc, 188Re, 186Re, 166Ho, 177Lu

Targeting Molecule

Requirements for target-specific radiopharmaceuticals

• Targeting molecule

with specific binding

to the target structure

(tumor, infection, etc)

Targeting Molecule

Targeting Molecule

• Suitable radionuclide

for imaging and therapy

with stable linkage to

the targeting molecule

Cancer Cell

Molecular Target

GMP Based

Radiopharmaceutical

Production Facility

Cyclotron CS30

Nuclear Reactor

PET-CT

SPECT-CT

Hospitals

Radiopharmaceuticals for Molecular Imaging

18F,124I, 96Zr,123I, 111In, 64Cu

RPs of 18F,124I, 96Zr, 64Cu

RPs of 123I,111In, 99mTc, 131I

99mTc, 131I

RPs= Radiopharmaceuticals

Radiopharmaceuticals developed by BATAN for

Nuclear Oncology:

• PET and SPECT radiopharmaceuticals, such as 18FDG, 18FLT, 123I-

MIBG, 99mTc-HYNIC Octreotide, 99mTc-HYNIC-Folate, etc.

• Therapeutic radiopharmaceuticals:

• 90Sr/90Y Therapeutic Generator

• PZC-Based 188W/188Re Therapeutic Generator

- 153Sm-EDTMP

- 186Re-HEDP

- 131I-MIBG

- 131I-Lipiodol

- 177Lu-DOTA-Nimotuzumab

- 177Lu-DOTA-TrastuzumabRadioimmunotherapy

RIA Kits developed by BATAN for Nuclear Oncology:

• IRMA Kit CA 125 for in vitro diagnosis of

ovarium cancer

• IRMA Kit CA 15.3 for in vitro diagnosis of

breast cancer

PACT Fundamentals

• National Cancer Control Programs:

• Radiation Medicine and the role of the BATAN and the IAEA

Prevention

Early Detection

Diagnosis and Treatment

Palliative Care

* Radiation Medicine includes both radiotherapy (or radiation

oncology) and diagnostic imaging involving the safe use of ionizing

radiation and nuclear medicine procedures.

BATAN’s Role for PACT/Nuclear Oncology:

• Conducts R&D on radiopharmaceuticals, RIA/IRMA Kits, and

brachytherapy sealed sources for PACT

• Provides production technology packages of radioisotopes and

radiopharmaceuticals developed by BATAN to be implemented by

national companies, such as PT Kimia Farma, PT Batantek, for

fullfiling national needs.

Program Action BATAN’s Contribution

• Early Detection • Develop RIA/IRMA Kits, PET and SPECT

radiopharmaceuticals as required by

Hospitals

• Diagnosis • Develop PET and SPECT

radiopharmaceuticals as required by

Hospitals

• Treatment or Therapy • Develop sealed sources (needle, seed) for

HDR and LDR Brachytherapy, CND

Brachytherapy, Targeted Therapeutic

Radiopharmaceuticals

• Palliative Care • Develop simple and targeted therapeutic

radiopharmaceuticals

Summary

• BATAN will actively involve to support PACT through the R&D

programs.

• BATAN will encourage a close relationship and communication

between BATAN’s institutes with hospitals/medical doctors to

develop radiopharmaceuticals/RIA and IRMA Kits, brachytherapy

sealed sources for suitable for local condition.

Thank you